Search

Displaying results 271 - 280 of 536 in total
  1. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.

  2. Drug

    Azathioprine

    go.drugbank.com/drugs/DB00993
    ApprovedInvestigational

    [L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]

    Products: AZATIOPRINA GENERICS
  3. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]

  4. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in

  5. Indication

    Premature Ventricular Contraction (PVC)

    go.drugbank.com/conditions/DBCOND0090285
    Drugs: Bisoprolol
    Synonyms: Ventricular premature complex, Ventricular ectopic complex
  6. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  7. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    FDA approved on March 6, 2012.

  8. Target

    Basement membrane-specific heparan sulfate proteoglycan core protein

    go.drugbank.com/bio_entities/BE0001031
    TargetHumans

    Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It se...

    Polypeptides: Basement membrane-specific heparan sulfate proteoglycan core protein
  9. Drug

    Entecavir

    go.drugbank.com/drugs/DB00442
    ApprovedInvestigational

    Food and Drug Administration (FDA) in March 2005.

  10. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.